Word

PONLIMSI

Status

Pending

Status Code

730

Status Date

Tuesday, April 30, 2024

Serial Number

97715304

Mark Type

4

Filing Date

Tuesday, December 13, 2022

Published for Opposition

Tuesday, October 24, 2023

Trademark Owner History

TEVA PHARMACEUTICALS USA, Inc. - Owner At Publication

Classifications

5 Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations

Trademark Events

Dec 16, 2022

New Application Entered

Dec 16, 2022

New Application Office Supplied Data Entered

Sep 12, 2023

Assigned To Examiner

Sep 18, 2023

Examiners Amendment -Written

Sep 18, 2023

Examiners Amendment E-Mailed

Sep 18, 2023

Notification Of Examiners Amendment E-Mailed

Sep 18, 2023

Examiner's Amendment Entered

Sep 18, 2023

Approved For Pub - Principal Register

Oct 4, 2023

Notification Of Notice Of Publication E-Mailed

Oct 24, 2023

Published For Opposition

Oct 24, 2023

Official Gazette Publication Confirmation E-Mailed

Dec 19, 2023

Noa E-Mailed - Sou Required From Applicant

Apr 30, 2024

Sou Teas Extension Received

Apr 30, 2024

Sou Extension 1 Filed

Apr 30, 2024

Sou Extension 1 Granted

May 1, 2024

Notice Of Approval Of Extension Request E-Mailed